➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Express Scripts

Last Updated: September 22, 2021

DrugPatentWatch Database Preview

Details for Patent: 7,374,747

Email this page to a colleague

« Back to Dashboard

Which drugs does patent 7,374,747 protect, and when does it expire?

Patent 7,374,747 protects EVOCLIN and is included in one NDA.

This patent has thirty patent family members in fifteen countries.

Summary for Patent: 7,374,747
Title:Pharmaceutical foam
Abstract:The present invention provides various pharmaceutically active topical delivery compositions. In particular, compositions of the present invention are present in a pressurized contained comprising a quick-breaking alcoholic foaming agent, such that when the composition is released, i.e., dispensed, from the pressurized container, a quick-breaking temperature sensitive foam is formed. In addition, the present invention provides various aspects related to such compositions, including methods for modulating a foam characteristic, methods for improving the shelf-life of a pharmaceutically active compound, methods for the percutaneous treatment of various diseases, infections, and illnesses, and methods for evaluating foam characteristics.
Inventor(s): Abram; Albert Zorko (Wantirna, AU), Hunt; Barry Thomas (Carnegie, AU)
Assignee: Stiefel Research Australia, Pty Ltd. (Rowville, AU)
Application Number:11/463,573
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,374,747
Patent Claim Types:
see list of patent claims
Use; Composition;

Drugs Protected by US Patent 7,374,747

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Mylan EVOCLIN clindamycin phosphate AEROSOL, FOAM;TOPICAL 050801-001 Oct 22, 2004 AT RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial Y TREATMENT OF ACNE VULGARIS ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 7,374,747

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 042906 ⤷  Free Forever Trial
Argentina 082432 ⤷  Free Forever Trial
Australia 2004206769 ⤷  Free Forever Trial
Australia 2009235974 ⤷  Free Forever Trial
Brazil PI0406905 ⤷  Free Forever Trial
Canada 2513773 ⤷  Free Forever Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.